

1 **Patient satisfaction with community pharmacist-led anticoagulation management**  
2 **services and its relationship with patient characteristics**

3 **ABSTRACT**

4 **Background:** Community pharmacist-led anticoagulation management service (CPAMS)  
5 offers international normalised ratio point-of-care testing of warfarin in a community pharmacy  
6 setting. It has now expanded with 7,344 patients enrolled in the service across 164 pharmacies  
7 in New Zealand. The clinical benefit of CPAMS has been shown to be superior, but patient  
8 satisfaction with the service has not been fully explored.

9 **Objective:** To develop a questionnaire to assess patient satisfaction with CPAMS and evaluate  
10 its psychometric properties. Additionally, to determine the level of patient satisfaction with  
11 CPAMS and identify determinants of satisfaction with CPAMS.

12 **Settings:** 1071 patients enrolled in CPAMS across New Zealand took part in the study

13 **Main outcome measure:** Satisfaction with CPAMS service

14 **Methods:** Adult patients taking warfarin and currently enrolled in CPAMS were recruited  
15 through the national international normalised ratio online system and invited to complete a 36-  
16 item survey assessing satisfaction with CPAMS. To identify the most important dimensions of  
17 patient satisfaction, exploratory factor analysis was used. Multivariate linear regression models  
18 were used to examine the effect of independent variables on patient satisfaction.

19 **Results:** A total of 305 patients completed the survey. The mean overall satisfaction score was  
20  $94.5\% \pm 13.1$  out of maximum possible points. Five dimensions of patient satisfaction were  
21 identified by factor analysis: patient-centred communication, confidence in pharmacist  
22 competence, patient-pharmacist relationship, confidence in CPAMS, and pharmacy  
23 environment. Being older and more frequent visits to the pharmacy were positively associated  
24 with patient satisfaction. Living more than 1km away from a pharmacy, and 'poor' self-  
25 perceived health status were negative predictors of patient satisfaction. Being Māori or of other  
26 ethnic minority was also associated with lower satisfaction scores, exploratory analysis  
27 suggests patient-pharmacist relationship is an important driver of these differences.

28 **Conclusions:** The high level of patient satisfaction further supports the effectiveness of  
29 CPAMS as a delivery model. Patient satisfaction is affected by age, frequency of pharmacy  
30 visits, ethnicity, travel distance to pharmacy, and perceived health status. Policy makers and

31 practitioners should consider the characteristics of patients with low levels of satisfaction to  
32 improve and enhance CPAMS engagement.

33 **Key words:** Community pharmacy, anticoagulation management, warfarin, patient  
34 satisfaction, pharmacy services, New Zealand

35

### 36 **Impact of findings on practice statements**

- 37 •
- 38 • Efforts to further improve satisfaction with CPAMS should pay attention to patients  
39 with poor perceived-health, ethnic minorities, younger patients, and those who live far  
40 from pharmacies and less frequently visit pharmacies.
- 41 • Given high patient satisfaction with CPAMS, expanding the availability of the service  
42 is an option worthy of consideration.
- 43 • CPAMS is a service that patients are enrolled in for a long time thus a longitudinal  
44 study is required to explore patient satisfaction throughout their enrolment in CPAMS  
45 and if/how their satisfaction impacts long-term clinical and economic outcomes.

46

## 47 INTRODUCTION

48 Although warfarin is a highly effective anticoagulant, it has a higher potential for adverse  
49 events due to its narrow therapeutic index(1)]. Maintaining warfarin doses within the  
50 therapeutic range is challenging in clinical practice due to intra- and inter-patient variability,  
51 and the susceptibility of warfarin to pharmacokinetic changes due to drug or food interaction,  
52 poor medication adherence or various disease states[(2)].

53 In New Zealand (NZ), most patients on warfarin are generally managed by their family doctor  
54 (or general practitioners - GPs)(3)]. In this model of care, patients visit a laboratory where a  
55 venous blood sample is collected and results are relayed, often electronically, to the general  
56 practice. The patient is contacted by telephone or contacts the practice themselves to receive  
57 INR results, information about warfarin dose adjustments, and the date of their next blood test.  
58 As there is not a consistent standardised way for patients to receive their INR results, some  
59 patients do not adjust their warfarin in time and /or do not receive consistent INR monitoring.  
60 This model of care is thought to cause fragmentation of the service (4). Additionally, this model  
61 of care puts a considerable burden on both patients and GPs, especially since warfarin therapy  
62 can be lifelong once initiated (4).

63 To address some of the problems with the current GP-led warfarin management system, and to  
64 improve the safety and efficacy of warfarin treatment, a community pharmacist-led  
65 anticoagulation management service (CPAMS) was introduced in NZ in 2013. In the CPAMS  
66 model, community pharmacists provide point-of-care INR testing (with a CoaguChek XS Plus  
67 or Pro device) using a capillary blood sample and adjust warfarin doses as needed using a  
68 decision support system, INR Online ([http:// www.inronline.net](http://www.inronline.net)). The test results are available  
69 within minutes to patients. Pharmacists providing CPAMS are accredited by attending the New  
70 Zealand Pharmaceutical Society prescribed training and operate under a Standing Order  
71 agreement between them and local GPs. The GP retains overall responsibility for a patient's  
72 management and can intervene at any time. The pharmacist is also able to consult with the GP  
73 regarding any abnormal or sudden changes in results. All INR test results are sent to the GPs  
74 computer system so that they always have a clear picture of the treatment progress. Over 7,300  
75 patients are currently enrolled in CPAMS across 164 community pharmacies nationwide(5).

76 The clinical benefits of CPAMS are evident(3,6) but what is unknown is how patients perceive  
77 the service. To date, there has only been one pilot study published that has explored satisfaction  
78 with CPAMS[(4)]. The pilot study participants reported improved accessibility and

79 convenience, and also commented that the more streamlined process has reduced potential  
80 delays and miscommunications. They also felt more involved with their treatment and had a  
81 better understanding of their health issues.

82 As CPAMS expands, there is a need to meet the diverse needs of the population of warfarin  
83 users. To achieve this, there is a need to assess and understand patient satisfaction and its  
84 influencing factors to ensure the long-term success of CPAMS. Evidence shows that satisfied  
85 patients maintain good relationships with their pharmacists[(7)]. This will enhance patient  
86 adherence to treatment regimens, ultimately leading to improved health outcomes.

## 87 **AIM OF THE STUDY**

88 This study aimed to develop a questionnaire to assess patient satisfaction with CPAMS and  
89 evaluate its psychometric properties. Additionally, the level of patient satisfaction with  
90 CPAMS across New Zealand were evaluated, and the relationship between patient  
91 characteristics and satisfaction with CPAMS were examined.

## 92 **ETHICS APPROVAL**

93 The study was approved by the University of Auckland Human Participants Ethics Committee  
94 (Ref no. 023597).

## 95 **METHODS**

### 96 **Study design and sample size**

97 We performed a cross-sectional study using a self-administered online survey to assess patient  
98 satisfaction with CPAMS. Exploratory factor analysis (EFA) and multivariable linear  
99 regression were the main statistical procedures used. A minimum of 200 participants(8)] or 5-  
100 10 participants per item(9,10) are recommended for EFA. A minimum of 10 participants per  
101 predictor variable is required for linear regression analysis(11)]. Six separate multivariate  
102 linear regression models were used in this study (see data analysis below) and 14 predictor  
103 variables were included in each of these models. Hence, a minimum sample size of 220 was  
104 required to conduct a robust statistical analysis using EFA and linear regression.

### 105 **Survey participants**

106 The study population included patients who were enrolled in CPAMS across NZ. The INR  
107 Online system is a computerised anticoagulant management system that offers automated

108 dosing and a recommended date for the next test[(12). This system was used to assist with  
109 recruitment by providing a list of all community pharmacies providing CPAMS and a  
110 comprehensive record of patients who were enrolled in CPAMS. Firstly, an invitation email  
111 was sent to all pharmacies providing CPAMS asking for permission to contact their patients.  
112 Then, an invitation email containing the online survey link was sent to all patients from  
113 consenting pharmacies.

#### 114 **Survey instrument**

115 As there was no established measure of satisfaction with CPAMS, a new questionnaire was  
116 developed based on available literature on patient satisfaction with pharmacy services(4,13-  
117 17) and the research team experience. Five members of the research team (NSTB, RBT, EM,  
118 SN and NW) conducted a literature search on MEDLINE, Embase, and International  
119 Pharmaceutical Abstracts, using keywords "patient satisfaction", "community pharmacist-led  
120 services", and anticoagulants." Only articles measuring patient satisfaction with a pharmacist-  
121 led service were reviewed. Likert-scale items were used to explore multiple aspects of CPAMS,  
122 such as the patient-pharmacist relationship, confidence in CPAMS, convenience and  
123 accessibility, and pharmacy setting in recognition of the complexity of determinants of  
124 satisfaction. Each Likert item was rated on a five-point scale ( 1 =strongly disagree, 2 =disagree,  
125 3=Neither agree nor disagree, 4=agree, and 5=strongly agree) with a higher positive score  
126 indicating higher satisfaction with CPAMS. Four Likert items were worded negatively to  
127 control for acquiescence, which is the tendency for participants to agree with any statement  
128 regardless of the content. Participants were also asked to indicate their level of overall  
129 satisfaction with CPAMS, using a visual analogue scale (0-100% score). Additionally,  
130 participants were asked to provide a single item rating of their overall health (excellent, very  
131 good, good, fair, or poor). These response options were merged into two categories for data  
132 analysis: "good health" (excellent, very good, and good) and "poor health" (fair, poor) to obtain  
133 more statistical power. Participants were also asked for the number of times they had visited  
134 their pharmacist in the three months prior to the survey, and the number of different  
135 medications they were taking at the time of the survey. Sociodemographic characteristics were  
136 also collected, such as age, gender, ethnicity, level of education, and annual household income.  
137 Finally, participants were asked the approximate distance they must travel in order to access  
138 CPAMS service. The questionnaire was designed to be self-administered, and all responses  
139 were voluntary.

140 To establish content validity, the questionnaires were reviewed by two experts specialising in  
141 pharmacy practice research. The experts were asked to provide written feedback about the  
142 clarity, quality, and scope of the questionnaire. After the experts' feedback had been considered  
143 and incorporated, the questionnaires were piloted on 25 individuals selected from the general  
144 public, using a 'think-aloud' protocol(18), to ensure content and face validity. The pilot  
145 participants went through the survey with a member of the research team (NSTB, RBT, EM,  
146 SN, or NW) and were asked to comment on the clarity, format, language, and any other issues  
147 observed. Structured probes were used to uncover how pilot participants interpreted questions  
148 to verify the understanding and readability. Example probes included: "Tell me in your own  
149 words what this question is asking," and "How did you decide on your answer to this question?"  
150 Based on participants' feedback, the survey was revised.

### 151 **Survey procedure**

152 An invitation email was sent to all CPAMS users in participating pharmacies along with a link  
153 to a website where the participants could access the survey questionnaires. The survey was  
154 created and hosted using Qualtrics survey platform (Qualtrics, Provo, UT). Administration of  
155 the survey began on August 28, 2019, and a reminder e-mail was sent to non-responders two  
156 weeks after the first e-mail to solicit additional responses. After eight weeks, the survey was  
157 closed to new participants.

### 158 **Data analysis**

159 The data were analysed using SPSS v25 (IBM, Armonk, NY, USA). Descriptive statistics were  
160 used to summarise survey participant characteristics. We performed an EFA with a principal  
161 axis factoring method(19) to identify specific dimensions of patient satisfaction. The Kaiser-  
162 Meyer-Olkin measure of sampling adequacy (KMO Index)(20) and Bartlett's sphericity  
163 test(21) were used to evaluate the appropriateness of the data for factor analysis. The KMO  
164 index ranges from 0 to 1, with index >0.50 considered suitable for factor analysis[(19). The  
165 Bartlett's sphericity test should be significant ( $p < 0.05$ ) for factor analysis to be suitable[(22).  
166 Before running a factor analysis, a correlations matrix of the Likert items was used to identify  
167 and remove highly correlated ( $>0.90$ ) items from the analysis.(8) Cronbach's alpha was  
168 calculated for coherent variables within each factor to determine their internal consistency, and  
169 an alpha value greater than 0.70 was considered as adequately reliable.(8) The number of  
170 factors identified was based on their interpretability, having an eigenvalue  $>1$ (20), and the  
171 shape of the scree plot(23). A Promax rotation (a type of oblique rotation) was employed to

172 simplify and clarify the factor structures[(19,22). A factor loading  $\geq 0.4$  was considered  
173 acceptable(24). Finally, all the items which had  $\geq 0.40$  loadings on a particular factor were  
174 combined to form a composite mean score (subscale) to represent dimensions/constructs of  
175 patient satisfaction with CPAMS. All negatively worded items were reverse scored before  
176 composite scores were created. The composite scores were scored from 1 to 5, with higher  
177 scores indicating greater satisfaction. The distribution of responses was examined to determine  
178 potential floor and ceiling effect (i.e., people responding at lowest and highest ends of the Likert  
179 scales for each item). There were only two missing values for the Likert items. As levels of  
180 missing data were minimal and missingness was completely at random, the Expectation  
181 Maximisation method was used to impute missing data.(8)

182 Six separate multivariate linear regression models were developed to examine the association  
183 between patient characteristics and satisfaction with CPAMS. There were six dependent  
184 variables: one overall satisfaction score and five subscales (composite mean scores) measuring  
185 specific dimensions of patient satisfaction. The same number of independent variables were  
186 included in each of the linear regression models. These were perceived general health status,  
187 frequency of pharmacy visits in three months prior to the survey, number of current  
188 medications, age, gender, ethnicity, level of education, annual household income, and travel  
189 distance from pharmacy. In all models, a two-tailed  $p < 0.05$  was considered statistically  
190 significant.

## 191 **RESULTS**

### 192 **Participants' characteristics**

193 A total of 164 community pharmacies were invited to take part in the study. Of these, 33  
194 provided consent for their patients to be contacted for recruitment between the 5th of August  
195 and the 3rd of September 2019. The online survey link was then emailed to the 1071 patients  
196 receiving CPAMS in the consenting pharmacies on the 28<sup>th</sup> of August 2019. The median  
197 duration of administration was nine minutes. Three hundred and five questionnaires completed  
198 by the study participants were received by the 27<sup>th</sup> of October 2019. As patients on warfarin  
199 enrolled in CPAMS may switch to other oral anticoagulant therapies (e.g. dabigatran and  
200 rivaroxaban) and therefore no longer use CPAMS, their information may still remain on the  
201 INR Online system. As such, the true response rate of the participants could not be calculated.

202 Most participants reported their health status to be good, very good or excellent (n=226,  
203 74.1%). Most participants (n=254, 83.2%) had three or more visits to their pharmacy in three  
204 months prior to the survey, and over half of the participants were taking more than 5  
205 medications a day (n=156, 51.1%). Most participants were male (n=172, 56.4%), over 65 years  
206 of age (n=195, 63.9%), and identified themselves as NZ European (i.e. New Zealanders of  
207 European descent) (n=227, 74.4%). Almost half of the participants (n=149, 48.9%) attended  
208 tertiary education, and over a third of them had an annual household income of NZ \$30,001  
209 (€17,220) to NZ \$70,000 (€40,175) (n=118, 38.7%). Most (n=259, 84.9%) were living more  
210 than 1km away from their pharmacy (see Table 1).

211 **\*\*Insert Table 1 here\*\***

## 212 **Psychometric Properties of the Questionnaire**

### 213 **Content and Face Validity**

214 The questionnaire items were drawn from the research team experience and published  
215 literature. The two experts agreed that the survey captured a wide range of factors that may  
216 impact CPAMS and suggested some changes. For example, they suggested to add a visual  
217 analogue scale to assess overall satisfaction with CPAMS. The pilot testing resulted in clarified  
218 terminology, removal or revision of unclear response options and questions. The initial  
219 questionnaire consisted of 30 Likert items assessing different aspects of patient satisfaction  
220 with CPAMS. After piloting and expert review, eight redundant Likert items were deleted, and  
221 several others were modified. The final survey contained 22 Likert items.

### 222 **Construct Validity and Reliability**

223 Table 2 displays the details of EFA of Likert items assessing patient satisfaction. A total of 305  
224 participants provided valid responses for the 22 Likert items assessing patient satisfaction with  
225 CPAMS (13.9 cases per item). Thus, the sample size was adequate for factor analysis. All the  
226 Likert items were subjected to EFA. The KMO index was 0.911 and Bartlett's test of sphericity  
227 was significant ( $p < 0.001$ ) providing support that the data were suitable for EFA. There were  
228 no very strong correlations (i.e. all correlations were  $< 0.9$ ) between the Likert items. Two items  
229 were removed because their factor loadings were  $< 0.4$ . The remaining 20 items loaded on five  
230 factors, and these five factors explained 65.6% of the total variance.

231 Four items were loaded on the first factor. These items assessed the patient experience of  
232 patient-centred communication with pharmacists. Hence, this factor was labelled "patient-  
233 centred communication" and had a Cronbach's alpha coefficient of 0.8. The second factor



234 consisted of four items with a Cronbach's alpha coefficient of 0.8. These items measured the  
235 patients' confidence in pharmacist clinical and medication management skills and labelled as  
236 "Confidence in pharmacist competence." The third factor comprised four high-loading items  
237 related to patient-pharmacist relationship and labelled as "patient-pharmacist relationship."  
238 The Cronbach's alpha coefficient for this factor was 0.9. The 4 items loaded on the fourth factor  
239 assessed patient's confidence in CPAMS service and if they would recommend the service to  
240 other people and was named "Confidence in CPAMS" and had a Cronbach's alpha coefficient  
241 of 0.8. The last factor consisted four items that asked participants to indicate the extent to which  
242 they agree with different statements describing the general pharmacy environment, such as  
243 privacy, convenience of location, layout and waiting time. This factor was labelled "pharmacy  
244 environment" with a Cronbach's alpha coefficient of 0.7.

245 \*\*Insert Table 2 here\*\*

#### 246 **Correlations between Factors (subscales)**

247 To assess how distinct each patient satisfaction subscale was from other subscales in the same  
248 matrix, the factor correlation matrix was examined (see Table 3). The results indicated that  
249 there were moderate correlations between factors, ranging from 0.458 between 'patient-centred  
250 communication' and 'confidence in CPAMS' to 0.690 between "confidence in pharmacist  
251 competence" and "patient-pharmacist relationship".

252 \*\*Insert Table 3\*\*

#### 253 **Level of patient satisfaction**

254 The mean overall satisfaction score was  $94.5\% \pm 13.1$  (range 3% to 100%). The highest mean  
255 value ( $4.84 \pm 0.619$ ) was observed for the item "My pharmacist treats me with dignity and  
256 respect", whereas the lowest mean score value ( $4.31 \pm 0.932$ ) was for the item "My pharmacist  
257 is aware of my medical history." The minimum and maximum values were the same for all  
258 Likert items - 1 and 5, respectively (see Table 2). There were no floor effects, but ceiling effects  
259 were apparent for most questionnaire items.

#### 260 **Predictors of patient satisfaction with CPAMS**

261 *Predictors of individual dimensions of satisfaction:* Table 3 shows patient characteristics  
262 associated with satisfaction with CPAMS in multivariable linear regression analyses. Due to  
263 incomplete demographic data, 14 cases were excluded, and the linear regression analyses were  
264 completed using 291 cases. Māori had significantly lower satisfaction with their relationship

265 with pharmacist than NZ Europeans ( $p=0.011$ ). Individuals who belong to non-Māori/non-NZ  
266 European ethnic groups had significantly lower satisfaction with pharmacy environment than  
267 did NZ Europeans ( $p=0.012$ ). Older patients had significantly higher satisfaction with  
268 pharmacy environment than younger patients ( $p=0.008$ ). Patients that lived between 1km and  
269 5km ( $p=0.017$ ) and over 5km ( $p=0.034$ ) away from CPAMS providing pharmacy reported  
270 lower satisfaction with pharmacy environment than those living within 1km from pharmacy.  
271 Patients with ‘poor’ perceived health reported significantly lower satisfaction with pharmacist  
272 competence in managing warfarin, compared to patients with ‘good’ perceived health  
273 ( $p=0.016$ ). Compared to those who visited a pharmacy twice or less, those who visited a  
274 pharmacy three times were more likely to have higher satisfaction scores for ‘pharmacy  
275 environment’ dimension ( $p<0.001$ ). Likewise, those who visited a pharmacy more than four  
276 times had higher satisfaction scores for dimensions of ‘pharmacy environment’ ( $p<0.001$ ),  
277 ‘patient-pharmacist relationship’ ( $p=0.014$ ), ‘confidence in pharmacist competence’ ( $p=0.049$ )  
278 and ‘patient centred communication’ ( $p=0.014$ ) compared with patients who visited a  
279 pharmacy twice or less. No statistically significant association was found between patient  
280 satisfaction and gender, level of education, annual household income, and number of current  
281 medications.

282 *Predictors of overall satisfaction:* Those who visited a pharmacy three times ( $p=0.012$ ) and  
283 more than four times ( $p=0.049$ ) had higher overall satisfaction with CPAMS compared with  
284 those who visited a pharmacy twice or less. No other variables had significant association with  
285 overall satisfaction (see Table 3).

286 \*\*Insert Table 4 here\*\*

## 287 **DISCUSSION**

### 288 **Psychometric Properties of the Questionnaire**

289 Our questionnaire demonstrated good validity and reliability. As there were no other validated  
290 tools for assessing satisfaction with CPAMS, criterion validity could not be established.  
291 Presence of moderate correlations between the factors (subscales), supported our initial  
292 assumption of using oblique (Promax) rotation.(19) A ceiling effect is often observed in patient  
293 satisfaction scales(25) as patients consistently tend to score their care in the mid-to-high range  
294 for most items. Our questionnaire is not an exception with this regard. This could be due to  
295 social desirability response bias, where patients report greater satisfaction than they feel,

296 believing positive responses will be more acceptable to the researcher.(26) Qualitative studies  
297 might help for in-depth exploration of patient satisfaction.

298 Extensive literature search, expert feedback, and the research team experience allowed for the  
299 selection of meaningful Likert items and constructs to measure satisfaction with CPAMS. The  
300 pilot study provided evidence for face validity as well as the understandability and readability  
301 of the questions. Our questionnaire may aid in conducting research to assess patient satisfaction  
302 with pharmacy-based anticoagulation services. However, as the healthcare system across  
303 countries vary greatly, this questionnaire may need adaption to local needs. As with all  
304 questionnaires, continuous testing and refinement is necessary.

### 305 **Predictors of Patient Satisfaction with CPAMS**

306 This study is the first to evaluate patients' satisfaction with CPAMS in NZ and identify  
307 predictors of patient satisfaction with CPAMS. Past studies have focused on investigating the  
308 association between overall satisfaction and patient characteristics[(27-29). However, overall  
309 measures of satisfaction are of limited use as they give little guidance as to how healthcare  
310 providers should respond to specific patient concerns[(30). To address this issue, our study  
311 examined predictors of specific dimensions of satisfaction as well as overall satisfaction score.  
312 Our findings support high patient satisfaction with pharmacist-led warfarin management  
313 services similar to that reported in prior research[(4,31-33).

314 ***Ethnicity:*** although satisfaction with CPAMS was generally high, inequities across groups  
315 were seen. Māori were found to have lower satisfaction with their relationship with pharmacist,  
316 and non-Māori ethnic minority patients had significantly lower satisfaction scores for the  
317 dimension of 'pharmacy environment', compared with NZ Europeans. This finding is in line  
318 with previous studies where NZ Europeans report higher satisfaction with health services than  
319 other ethnic groups[(34). This could be due to the language or cultural barriers that ethnic  
320 minority groups experience within the current healthcare setting[(35). Thus, improving the  
321 structure of CPAMS to be more culturally appropriate may increase uptake by Māori patients  
322 and other minority groups. CPAMS operates on a predominantly medical model of health with  
323 minimal focus on the holistic care of patients. Incorporating the *Te Whare Tapa Whā*, a Māori  
324 model of health that includes spiritual, family, mental and physical health[(36), into the current  
325 practice may help to maximise satisfaction and participation in CPAMS in Māori and other  
326 ethnic minorities. This model aims to reduce cultural barriers and promote culturally  
327 appropriate care.

328 **Age:** this study also found that older patients have a higher degree of satisfaction with the  
329 'pharmacy environment' dimension than younger patients, which is similar to findings from  
330 other studies on satisfaction with healthcare services[(37-40)]. This may be because older  
331 patients have lower or more realistic expectations from their pharmacists than younger patients  
332 rather than actual differences in the quality of service received by the two groups[(41). It has  
333 also been noted that individuals who lived longer and experienced significant hardships may  
334 be more accepting of inadequacies in the healthcare system than younger individuals[(41,42).

335 **Perceived Health Status:** Prior research indicated that a low health status leads to lower patient  
336 satisfaction scores[(29,39) which concurs with the findings of the present study. However, this  
337 finding requires cautious interpretation. As noted by Xiao and Barber, patients who perceive  
338 themselves to be in poor health may report lower patient satisfaction because they may attribute  
339 their poorer health with the healthcare they receive[(39). Furthermore, other personal  
340 characteristics unrelated to healthcare services may affect satisfaction. For example, patient  
341 dissatisfaction with the healthcare services could be a manifestation of dissatisfaction with  
342 life[(43). The present study only assessed the effect of general health status on satisfaction,  
343 further studies are needed to explore the independent contribution of self-reported physical and  
344 mental health to patient satisfaction with CPAMS.

345 **Frequency of Pharmacy Visit:** in line with previous study[(44) our study showed that  
346 participants with more frequent visits to the pharmacy had a higher level of satisfaction across  
347 the different dimensions of patient satisfaction. A possible explanation is that more frequent  
348 visits may allow for more engagement of pharmacists with patients, thus more opportunities  
349 for detection of medication-related issues, monitoring of treatment regimens, and identification  
350 of health complications that might compromise outcomes, all of which could lead to better  
351 patient satisfaction. Additionally, patients who frequently visit pharmacies are likely to know  
352 their pharmacist better and develop better relationships, which might have positive impact on  
353 satisfaction. However, the present study did not examine the nature and duration of pharmacist-  
354 patient encounters. The quality and length of pharmacist-patient encounters is likely to be more  
355 important predictor of patient satisfaction than the frequency of visits and requires further  
356 investigation. It should also be noted that it is difficult to establish the cause-effect relationship  
357 in cross-sectional survey. Participants might have visited the pharmacy more often because  
358 they were satisfied with it.

359 ***Travel Distance to Pharmacy:*** travel distance to the pharmacy, specifically living more than  
360 1km from the pharmacy, was a significant predictor of lower satisfaction for ‘pharmacy  
361 environment’ dimension of patient satisfaction. This finding is expected considering that  
362 transportation barriers tend to increase with distance. Such problems as transportation costs,  
363 difficulties in finding convenient, public transportation or parking spaces (in larger cities), and  
364 increased travel time may have an adverse effect on patient satisfaction. Most of the study  
365 participants were also older, thus travelling longer distances for appointments could be  
366 strenuous especially for the very old and those living in poverty. A limited number of  
367 pharmacies provide CPAMS, thus it is important to ensure people in high-need areas have  
368 adequate access to the service. CPAMS is particularly relevant in rural settings because of the  
369 relative lack of access to laboratory services, uneven distribution of general practises, and  
370 shortages of GPs in rural areas[(4,45). Thus, priority funding to pharmacies in rural areas  
371 should be used to decrease barriers to access and improve patient outcomes as well as reducing  
372 pressure on already stretched general practice.

### 373 **Strengths and Limitations**

374 This study has some limitations. First, although all 164 pharmacies providing CPAMS were  
375 invited to take part, only 33 consented (20.1% response rate), with a high proportion of  
376 participants from urban areas in North Island. Response rates from other parts of NZ in contrast  
377 were low. This limits the generalisability of the findings. However, the ethnic, gender, and age  
378 distribution of our sample was approximately equivalent to that of the general population of  
379 CPAMS users, where the majority of CPAMS users were NZ Europeans, male, and older than  
380 65 years of age, according to 2018 estimates.(5) There is also a potential for CPAMS providers  
381 who have poor patient satisfaction to opt not of participating in this survey which could lead to  
382 response bias. Second, recruitment into this study was voluntary and therefore it is uncertain  
383 whether the sample was biased. Third, high patient satisfaction could have been reported due  
384 to social desirability bias or patients’ hesitancy to negatively evaluate care providers (46).  
385 Finally, a ‘new’ questionnaire was used to assess satisfaction with CPAMS due to lack of  
386 existing suitable measures. However, the questionnaire showed good internal consistency, and  
387 construct, content and face validity and could be used by future researchers.

388 Despite the above limitations, this study is one of the few studies that explored patient  
389 satisfaction with CPAMS in NZ. The findings may contribute to informing policymakers and  
390 health providers in improving the service going forward.

### 391 **CONCLUSIONS**

392 This study investigated patient satisfaction with CPAMS. We have developed a new  
393 questionnaire capable of assessing patient satisfaction with CPAMS, which has demonstrated

394 good psychometric properties and a meaningful structure. The level of patient satisfaction with  
395 CPAMS was high. Older patients and those who had more frequent pharmacy visits exhibited  
396 greater satisfaction. Conversely, Māori and other ethnic minorities, individuals with poor  
397 perceived health status, and those who live more than 1km away from CPAMS providing  
398 pharmacy had lower satisfaction. Health policy makers and pharmacy practitioners should  
399 consider the characteristics of these patients with low levels of satisfaction to improve and  
400 enhance CPAMS. CPAMS is a service that patients are enrolled in for a long time, thus a  
401 longitudinal study is needed to explore if/how patient satisfaction changes over time. Further  
402 studies should investigate additional modifiable and non-modifiable factors that may influence  
403 patient satisfaction with CPAMS to ensure that this innovative service is sustained, and more  
404 patients can benefit from the positive clinical outcomes seen with CPAMS.

#### 405 **ACKNOWLEDGEMENTS**

406 We would like to thank all the study participants.

#### 407 **FUNDING**

408 This research did not receive any specific grant from funding agencies in the public,  
409 commercial, or not-for-profit sectors.

#### 410 **CONFLICTS OF INTEREST**

411 There are no competing interests to declare.

412

413 **References**

- 414 (1) Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a  
415 prevalent adverse effect resulting in regulatory action. *Arch Intern Med.* 2007;167:1414-  
416 1419.
- 417 (2) Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and  
418 management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic  
419 and Thrombolytic Therapy. *Chest.* 2004;126:204S-233S.
- 420 (3) Harper P, McMichael I, Griffiths D, Harper J, Hill C. The community pharmacy-based  
421 anticoagulation management service achieves a consistently high standard of anticoagulant  
422 care. *N Z Med J.* 2015;128:31-41.
- 423 (4) Shaw J, Harrison J, Harrison J. A community pharmacist-led anticoagulation management  
424 service: attitudes towards a new collaborative model of care in New Zealand. *Int J Pharm*  
425 *Pract.* 2014;22:397-406.
- 426 (5) TAS Health. Community Pharmacy Anti-Coagulation Management Service Quality  
427 Report - July to December 2018. [https://tas.health.nz/assets/Community-pharmacy/CPAMS-](https://tas.health.nz/assets/Community-pharmacy/CPAMS-QReport-Jul-Dec-2018.pdf)  
428 [QReport-Jul-Dec-2018.pdf](https://tas.health.nz/assets/Community-pharmacy/CPAMS-QReport-Jul-Dec-2018.pdf). Accessed 24 June 2020.
- 429 (6) Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community  
430 pharmacists in New Zealand: an evaluation of a collaborative model in primary care. *Int J*  
431 *Pharm Pract.* 2015;23:173-181.
- 432 (7) Covinsky KE, Rosenthal GE, Chren M, Justice AC, Fortinsky RH, Palmer RM, et al. The  
433 relation between health status changes and patient satisfaction in older hospitalized medical  
434 patients. *J Gen Intern Med.* 1998;13:223-229.
- 435 (8) Tabachnick BG, Fidell LS. *Using multivariate statistics.* 5th ed. Boston: Allyn and Bacon;  
436 2007. ISBN 9780134790541
- 437 (9) Everitt B. Multivariate analysis: the need for data, and other problems. *Br J Psychiatry.*  
438 1975;126:237-240.
- 439 (10) Kline R. Nunnally, JC, & Bernstein, IH (1994). *Psychometric theory.* *J Psychoeduc*  
440 *Assess.* 1999;17:275-280.
- 441 (11) Miller DE, Kuncze JT. Prediction and statistical overkill revisited. *Meas Eval Guide.*  
442 1973;6:157-163.
- 443 (12) Harper P, Harper J, Hill C. An audit of anticoagulant management to assess  
444 anticoagulant control using decision support software. *BMJ Open.* 2014;4(9):e005864-2014-  
445 005864.
- 446 (13) Schommer JC, Kucukarslan SN. Measuring patient satisfaction with pharmaceutical  
447 services. *Am J Health Syst Pharm.* 1997;54:2721-32.

- 448 (14) Al-Abri R, Al-Balushi A. Patient satisfaction survey as a tool towards quality  
449 improvement. *Oman Med J*. 2014;29:3-7.
- 450 (15) Bishop L, Young S, Twells L, Dillon C, Hawboldt J. Patients' and physicians'  
451 satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic.  
452 *BMC Res Notes*. 2015;8(1):233.
- 453 (16) Willey ML, Chagan L, Sisca TS, Chapple KJ, Callahan AK, Crain JL, et al. A  
454 pharmacist-managed anticoagulation clinic: six-year assessment of patient outcomes. *Am J*  
455 *Health Syst Pharm*. 2003;60:1033-1037.
- 456 (17) Ingram SJ, Kirkdale CL, Williams S, Hartley E, Wintle S, Sefton V, et al. Moving  
457 anticoagulation initiation and monitoring services into the community: evaluation of the  
458 Brighton and Hove community pharmacy service. *BMC Health Serv Res*. 2018;18(1):91.
- 459 (18) Fonteyn ME, Kuipers B, Grobe SJ. A description of think aloud method and protocol  
460 analysis. *Qual Health Res*. 1993;3:430-441.
- 461 (19) Costello AB, Osborne JW. Best practices in exploratory factor analysis: four  
462 recommendations for getting the most from your analysis. *Pract Assess Res Evaluation*.  
463 2005;10:1-9.
- 464 (20) Kaiser HF. The application of electronic computers to factor analysis. *Educ Psychol*  
465 *Meas*.1960;20:141-151.
- 466 (21) Bartlett MS. Tests of significance in factor analysis. *Brit J Math Stat Psy*. 1950;3:77-85.
- 467 (22) Fabrigar LR, Wegener DT, MacCallum RC, Strahan EJ. Evaluating the use of  
468 exploratory factor analysis in psychological research. *Psychol Methods*. 1999;4:272-299.
- 469 (23) Cattell RB. The scree test for the number of factors. *Multivariate Behav Res*.  
470 1966;1:245-276.
- 471 (24) Kachigan SK. *Multivariate statistical analysis: A conceptual introduction*. 2nd ed. New  
472 York: Radius Press; 1991. ISBN-13: 978-0942154917.
- 473 (25) Cappelleri JC, Gerber RA, Kourides IA, Gelfand RA. Development and factor analysis  
474 of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1  
475 diabetes. *Diabetes Care*. 2000;23:1799-1803.
- 476 (26) Biering P, Becker H, Calvin A, Grobe SJ. Casting light on the concept of patient  
477 satisfaction by studying the construct validity and the sensitivity of a questionnaire. *Int J*  
478 *Health Care Qual Assur*. 2006;19:246-58.
- 479 (27) Kressin NR, Skinner K, Sullivan L, Miller DR, Frayne S, Kazis L, et al. Patient  
480 satisfaction with Department of Veterans Affairs health care: do women differ from men?  
481 *Mil Med*. 1999;164:283-288.



- 482 (28) Al-Sakkak MA, Al-Nowaiser NA, Al-Khashan HI, Al-Abdrabulnabi AA, Jaber RM.  
483 Patient satisfaction with primary health care services in Riyadh. Saudi Med J.  
484 2008;29(3):432.
- 485 (29) Alberto Sánchez C, Javier Prado-Galbarro F, García-Pérez S, Sarría Santamera A.  
486 Factors associated with patient satisfaction with primary care in Europe: results from the  
487 EUprimecare project. Qual Prim Care. 2014;22:147-55.
- 488 (30) Carr-Hill RA. The measurement of patient satisfaction. J Public Health. 1992;14:236-  
489 249.
- 490 (31) Garwood CL, Dumo P, Baringhaus SN, Laban KM. Quality of anticoagulation care in  
491 patients discharged from a pharmacist-managed anticoagulation clinic after stabilization of  
492 warfarin therapy. Pharmacotherapy. 2008;28:20-26.
- 493 (32) Bishop L, Young S, Twells L, Dillon C, Hawboldt J. Patients' and physicians'  
494 satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic.  
495 BMC Res Notes. 2015;8(1):233.
- 496 (33) Jackson SL, Peterson GM, House M, Bartlett T. Point-of-care monitoring of  
497 anticoagulant therapy by rural community pharmacists: Description of successful outcomes.  
498 Aust J Rural Health. 2004;12:197-200.
- 499 (34) Lee C, Sibley CG. Demographic and psychological correlates of satisfaction with  
500 healthcare access in New Zealand. N Z Med J. 2017;130:11-24.
- 501 (35) Jansen P, Bacal K, Crengle S. He Ritenga Whakaaro: Māori experiences of health  
502 services. 2008.  
503 [https://www.moh.govt.nz/notebook/nbbooks.nsf/0/2A6CAF401ABBEFB9CC2575F4000B6](https://www.moh.govt.nz/notebook/nbbooks.nsf/0/2A6CAF401ABBEFB9CC2575F4000B6D0C/$file/He-Ritenga-Whakaaro.pdf)  
504 [D0C/\\$file/He-Ritenga-Whakaaro.pdf](https://www.moh.govt.nz/notebook/nbbooks.nsf/0/2A6CAF401ABBEFB9CC2575F4000B6D0C/$file/He-Ritenga-Whakaaro.pdf) Accessed 24 June 2020.
- 505 (36) Durie M. Te Pae Mahutonga: A model for Maori health promotion. 1999.  
506 <https://www.cph.co.nz/wp-content/uploads/TePaeMahutonga.pdf> Accessed 24 June 2020.
- 507 (37) Carmel S. Satisfaction with hospitalization: a comparative analysis of three types of  
508 services. Soc Sci Med. 1985;21:1243-1249.
- 509 (38) Tucker III JL, Kelley VA. The influence of patient sociodemographic characteristics on  
510 patient satisfaction. Mil Med. 2000;165:72-76.
- 511 (39) Xiao H, Barber JP. The effect of perceived health status on patient satisfaction. Value  
512 Health. 2008;11:719-725.
- 513 (40) Hall JA, Dornan MC. Patient sociodemographic characteristics as predictors of  
514 satisfaction with medical care: a meta-analysis. Soc Sci Med. 1990;30:811-818.
- 515 (41) Cohen G. Age and health status in a patient satisfaction survey. Soc Sci Med.  
516 1996;42:1085-1093.

- 517 (42) Goodsell CT. The contented older client of bureaucracy. *Int J Aging Hum Dev.*  
518 1982;14:1-9.
- 519 (43) Weiss GL. Patient satisfaction with primary medical care. Evaluation of  
520 sociodemographic and predispositional factors. *Med Care.* 1988;26:383-392.
- 521 (44) Lee S, Godwin OP, Kim K, Lee E. Predictive Factors of Patient Satisfaction with  
522 Pharmacy Services in South Korea: A Cross-Sectional Study of National Level Data. *PLoS*  
523 *ONE.* 2015;10(11):e0142269.
- 524 (45) Jackson S, Peterson G, Bereznicki L, Misan G, Jupe D, Vial J. Improving the outcomes  
525 of anticoagulation in rural Australia: an evaluation of pharmacist-assisted monitoring of  
526 warfarin therapy. *J Clin Pharm Ther.* 2005;30:345-353.
- 527 (46) Ware Jr JE, Snyder MK, Wright WR, Davies AR. Defining and measuring patient  
528 satisfaction with medical care. *Eval Program Plann.* 1983;6:247-263.
- 529

530 **Table 1:** Characteristic of survey participants (N=305)

| <b>Variables</b>   | <b>N</b> | <b>%</b> |
|--|----------|----------|
| <b>Gender</b>  |          |          |
| Male   | 172      | 56.4     |
| Female   | 132      | 43.3     |
| Missing  | 1        | 0.3      |
| <b>Age groups (in years)</b>   |          |          |
| <35 years  | 6        | 1.9      |
| 35 to 44 years   | 14       | 4.6      |
| 45 to 54 years   | 23       | 7.5      |
| 55 to 64 years   | 67       | 22.0     |
| 65 or older  | 195      | 63.9     |
| <b>Ethnic group</b>  |          |          |
| NZ European  | 227      | 74.4     |
| Other  | 78       | 25.6     |
| <b>What is the highest education level you have achieved so far?</b>                             |          |          |
| No schooling completed   | 5        | 1.6      |
| Primary school   | 2        | 0.7      |
| Secondary School (three years or less)   | 67       | 22.0     |
| Secondary School (more than three years)   | 81       | 26.6     |
| Tertiary education (polytechs, college, or university)   | 149      | 48.9     |
| Missing  | 1        | 0.3      |
| <b>What was your total household income before taxes during the past 12 months?</b>              |          |          |
| ≤ \$30,000   | 57       | 18.7     |
| \$30,001 – \$70,000  | 118      | 38.7     |
| >\$70,000  | 128      | 41.9     |
| Missing  | 2        | 0.7      |
| <b>At what approximate distance you are living from your current pharmacy?</b>                   |          |          |
| < 1km  | 46       | 15.1     |
| 1-5km  | 172      | 56.4     |
| 6-10km   | 42       | 13.8     |
| Over 10km  | 45       | 14.8     |
| <b>In general, would you say your health is:</b>   |          |          |
| Excellent  | 17       | 5.6      |
| Very good  | 99       | 32.5     |
| Good   | 110      | 36.1     |
| Fair   | 62       | 20.3     |
| Poor   | 17       | 5.6      |
| <b>How many different medications do you take each day?</b>                                      |          |          |
| One  | 23       | 7.5      |
| Two  | 35       | 11.5     |
| Three  | 40       | 13.1     |
| Four   | 51       | 16.7     |
| ≥Five  | 156      | 51.1     |
| <b>How often did you visit your pharmacist for your warfarin treatment in the last 3 months?</b> |          |          |
| Once   | 10       | 3.3      |
| Twice  | 32       | 10.5     |
| Three times  | 107      | 35.1     |
| Four times   | 29       | 9.5      |
| Five times   | 39       | 12.8     |

|                 |    |      |
|-----------------|----|------|
| Over five times | 79 | 25.9 |
| Missing         | 9  | 3.0  |

531

532

533

534 **Table 2:** Mean scores and factor loadings of the 20 items retained in the final EFA of patient  
 535 satisfaction with CPAMS (N=305).

| Item <sup>a</sup>  | Mean      | Factors      |              |              |              |              |
|--|-----------|--------------|--------------|--------------|--------------|--------------|
|  |           | 1            | 2            | 3            | 4            | 5            |
| My pharmacist provides clear explanations about my medications.                                  | 4.71±0.70 | <b>0.793</b> | -0.047       | 0.036        | -0.025       | -0.023       |
| My pharmacist listens to my health concerns.   | 4.64±0.75 | <b>0.666</b> | 0.221        | -0.053       | -0.073       | 0.035        |
| My pharmacist involves me in making decisions about my medications.                              | 4.48±0.90 | <b>0.587</b> | 0.061        | 0.099        | 0.131        | -0.026       |
| My pharmacist provides clear explanations about the results of my blood test.                    | 4.79±0.62 | <b>0.442</b> | 0.318        | -0.002       | 0.003        | 0.045        |
| I am confident with my pharmacist's skills in managing my warfarin treatment.                    | 4.78±0.64 | 0.036        | <b>0.915</b> | -0.012       | 0.088        | -0.080       |
| I feel confident about my pharmacist's ability to accurately perform my blood test.              | 4.83±0.62 | 0.044        | <b>0.644</b> | 0.064        | -0.014       | -0.046       |
| My pharmacist is aware of my medical history.  | 4.31±0.93 | 0.124        | <b>0.550</b> | 0.002        | -0.056       | 0.027        |
| My pharmacist keeps my family doctor informed about my warfarin testing.                         | 4.42±0.97 | 0.038        | <b>0.522</b> | 0.016        | 0.017        | 0.017        |
| I feel comfortable discussing my concerns with my pharmacist.                                    | 4.74±0.74 | 0.012        | 0.147        | <b>0.896</b> | -0.042       | -0.074       |
| My pharmacist treats me with dignity and respect.  | 4.84±0.62 | -0.054       | 0.049        | <b>0.847</b> | 0.056        | 0.026        |
| My pharmacist has expressed genuine interest in my well-being.                                   | 4.71±0.74 | 0.292        | -0.053       | <b>0.639</b> | 0.011        | -0.010       |
| My pharmacist DOES NOT spend enough time with me. <sup>b</sup>                                   | 4.80±0.68 | 0.287        | -0.132       | <b>0.469</b> | -0.044       | 0.088        |
| I would rather have my blood taken by a finger-prick than by a needle in my arm.                 | 4.83±0.61 | -0.176       | 0.219        | -0.050       | <b>0.746</b> | -0.130       |
| I prefer having my warfarin managed by my pharmacist rather than my family doctor.               | 4.37±0.97 | 0.201        | -0.195       | -0.002       | <b>0.725</b> | -0.023       |
| I believe other patients on warfarin would benefit from this service.                            | 4.80±0.60 | -0.007       | -0.004       | 0.008        | <b>0.686</b> | 0.013        |
| Having my warfarin tested at my pharmacy makes me feel more in control of my warfarin treatment. | 4.61±0.80 | -0.007       | 0.043        | 0.120        | <b>0.430</b> | 0.225        |
| The waiting area of my pharmacy is adequate.   | 4.45±0.88 | 0.040        | 0.004        | -0.103       | -0.018       | <b>0.889</b> |
| The pharmacy layout ensures my privacy.  | 4.68±0.74 | 0.055        | 0.093        | -0.034       | 0.106        | <b>0.589</b> |
| The waiting time at my pharmacy is too long. <sup>b</sup>  | 4.36±1.12 | 0.006        | -0.112       | 0.047        | -0.081       | <b>0.480</b> |
| I find my pharmacy to be conveniently located.   | 4.70±0.71 | -0.202       | 0.229        | 0.276        | -0.043       | <b>0.423</b> |
| Cronbach's alpha   |           | 0.8          | 0.8          | 0.9          | 0.8          | 0.7          |
| Eigenvalue   |           | 8.47         | 1.56         | 1.23         | 1.05         | 1.00         |
| % Variance explained by each factor  |           | 41.8         | 7.8          | 6.1          | 5.2          | 4.6          |
| Total variance explained   |           | 65.6%        |              |              |              |              |

536 Extraction Method: Principal Axis Factoring  
 537 Rotation Method: Promax with Kaiser Normalization

538 Strong factor loadings (>0.4) are highlighted in bold  
 539 Mean Score = Mean (xi, xii, xiii, xiv, ...); SD=standard deviation  
 540 <sup>a</sup>Responses for each item were presented on a 5-point Likert scale ranging from 1 (Strongly  
 541 Disagree) to 5 (Strongly Agree)  
 542 <sup>b</sup>Reverse scored items

543  
 544

545 **Table 3: Factor correlation matrix showing correlation between satisfaction with**  
 546 **CPAMS subscales**

|                                     | <b>Correlation</b>                       |                                     |                                 |                     |                      |
|-------------------------------------|--|-------------------------------------|---------------------------------|---------------------|----------------------|
|                                     | <b>Satisfaction with CPAMS subscales</b> |                                     |                                 |                     |                      |
|                                     | Patient-centred communication            | Confidence in pharmacist competence | Patient-pharmacist relationship | Confidence in CPAMS | Pharmacy environment |
| Patient-centred communication       | 1.000                                    |                                     |                                 |                     |                      |
| Confidence in pharmacist competence | 0.582                                    | 1.000                               |                                 |                     |                      |
| Patient-pharmacist relationship     | 0.662                                    | 0.690                               | 1.000                           |                     |                      |
| Confidence in CPAMS                 | 0.458                                    | 0.673                               | 0.559                           | 1.000               |                      |
| pharmacy environment                | 0.536                                    | 0.642                               | 0.597                           | 0.573               | 1.000                |

547 \*CPAMS = Community pharmacy-led anticoagulation management service

**Table 4:** Multivariate linear regression models examining the predictors of patient satisfaction with CPAMS (N=291).

| Variable                                       | Patient-centred communication |              | Confidence in pharmacist competence |              | Patient-Pharmacist relationship |              | Confidence in CPAMS |         | Pharmacy environment |                  | Overall satisfaction |              |
|--|-------------------------------|--------------|-------------------------------------|--------------|---------------------------------|--------------|---------------------|---------|----------------------|------------------|----------------------|--------------|
|  | $\beta$                       | p-value      | $\beta$                             | p-value      | $\beta$                         | p-value      | $\beta$             | p-value | $\beta$              | p-value          | $\beta$              | p-value      |
| <b>Gender</b>                                  |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| Female   | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| Male   | -0.059                        | 0.341        | -0.092                              | 0.139        | -0.057                          | 0.355        | -0.082              | 0.187   | -0.071               | 0.227            | -0.026               | 0.669        |
| <b>Age group (in years)</b>                    |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| <65  | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| $\geq 65$                                      | 0.009                         | 0.898        | 0.095                               | 0.157        | 0.058                           | 0.386        | 0.126               | 0.060   | 0.168                | <b>0.008</b>     | 0.065                | 0.331        |
| <b>Ethnic group</b>                            |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| NZ European                                    | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| Māori  | -0.070                        | 0.266        | -0.007                              | 0.915        | -0.161                          | <b>0.011</b> | 0.003               | 0.960   | 0.013                | 0.825            | -0.040               | 0.522        |
| Other  | -0.008                        | 0.891        | -0.043                              | 0.481        | -0.100                          | 0.099        | 0.007               | 0.905   | -0.146               | <b>0.012</b>     | -0.083               | 0.169        |
| <b>Level of educational</b>                    |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| Attended tertiary education                    | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| Didn't attend tertiary education               | -0.020                        | 0.741        | 0.046                               | 0.442        | -0.009                          | 0.884        | 0.053               | 0.381   | 0.109                | 0.056            | 0.056                | 0.350        |
| <b>Annual household income (NZ \$)</b>         |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| $\leq$ \$30,000                                | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| \$30,001 – \$70,000                            | 0.017                         | 0.800        | -0.026                              | 0.690        | 0.008                           | 0.904        | -0.042              | 0.525   | 0.029                | 0.642            | 0.073                | 0.270        |
| $>$ \$70,000                                   | -0.065                        | 0.359        | -0.042                              | 0.547        | 0.011                           | 0.878        | 0.104               | 0.139   | 0.037                | 0.575            | 0.085                | 0.225        |
| <b>Travel distance to pharmacy</b>             |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| $<$ 1km  | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| 1-5km  | -0.015                        | 0.866        | 0.076                               | 0.383        | 0.065                           | 0.454        | -0.019              | 0.828   | -0.199               | <b>0.017</b>     | 0.042                | 0.630        |
| $>$ 5km  | 0.033                         | 0.711        | 0.041                               | 0.642        | 0.020                           | 0.815        | -0.099              | 0.259   | -0.176               | <b>0.034</b>     | -0.111               | 0.202        |
| <b>General health status</b>                   |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| Good   | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| Poor   | -0.066                        | 0.285        | -0.149                              | <b>0.016</b> | -0.032                          | 0.600        | 0.011               | 0.859   | -0.078               | 0.180            | -0.043               | 0.487        |
| <b>No. of current medications</b>              |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| $<$ Five                                       | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| $\geq$ Five                                    | 0.026                         | 0.676        | 0.066                               | 0.288        | -0.019                          | 0.753        | -0.033              | 0.593   | 0.060                | 0.308            | -0.083               | 0.180        |
| <b>Frequency of pharmacy visit in 3 months</b> |                               |              |                                     |              |                                 |              |                     |         |                      |                  |                      |              |
| $<$ Three                                      | Ref.                          | --           | Ref.                                | --           | Ref.                            | --           | Ref.                | --      | Ref.                 | --               | Ref.                 | --           |
| Three  | 0.024                         | 0.787        | 0.068                               | 0.442        | 0.062                           | 0.486        | 0.131               | 0.141   | 0.368                | $<$ <b>0.001</b> | 0.225                | <b>0.012</b> |
| Four   | 0.000                         | 0.995        | -0.028                              | 0.697        | 0.016                           | 0.821        | -0.084              | 0.244   | 0.090                | 0.190            | 0.060                | 0.400        |
| Over four                                      | 0.223                         | <b>0.014</b> | 0.177                               | <b>0.049</b> | 0.220                           | <b>0.014</b> | 0.170               | 0.059   | 0.354                | $<$ <b>0.001</b> | 0.177                | <b>0.049</b> |
| % variance explained by regression model       | 6%                            |              | 7%                                  |              | 8%                              |              | 7.5%                |         | 17%                  |                  | 8%                   |              |

$\beta$  = Standardised coefficient beta; p-value  $<$  0.05 was considered statistically significant, and the corresponding confidence interval was 95%.